History | Enzalutamide for treating hormone-sensitive metastatic prostate cancer | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Published:

07 July 2021

Declaration of interests

Register of interests (MSWord 41 KB)

Published:

26 August 2021

Final draft guidance

Final draft guidance
Public committee slides (PDF 866 KB)

Published:

08 June 2021
Committee papers (PDF 4.17 MB)

Published:

08 June 2021
Final appraisal document (PDF 284 KB)

Published:

08 June 2021

Notes

Note
Note

Invitation to participate

Final scope (PDF 183 KB)

Published:

04 September 2019
Final stakeholder list (PDF 188 KB)

Published:

04 September 2019
Equality impact assessment (Scoping) (PDF 123 KB)

Published:

04 September 2019
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 249 KB)

Published:

05 September 2019

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 219 KB)

Published:

09 July 2019
Draft matrix post referral (PDF 188 KB)

Published:

09 July 2019